Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269048 · ClinicalTrials.gov registry record · Phase 2
SB-480848 In Subjects With Coronary Heart Disease
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 969
- Enrollment target
NCT00269048: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00269048 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 969 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (629% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00269048, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 969 participants
- Enrollment target
Study Summary
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of SB-480848 on other circulating biomarkers associated with cardiovascular risk, and evaluate the pharmacokinetics, safety and tolerability of SB-480848 over 12 weeks of once-daily oral dosing. Subjects will first be randomized 1:1 to double-blind atorvastatin 20 mg or 80 mg once daily for a minimum of 3 weeks. Subjects will then be randomized 1:1:1:1 to oral doses of SB-480848 40 mg, 80 mg, 160 mg or placebo once daily for 12 weeks. Blood samples will be collected at various timepoints. Vital signs, electrocardiograms, clinical laboratory safety tests and adverse event assessments will be performed to evaluate the safety and tolerability of SB-480848.
Interventions
- DRUG placebo
- DRUG SB-480848
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 969 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00269048 record still lists
NCT00269048 is an interventional study that assigns participants to a tested intervention. The registered 969 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (629% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00269048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00269048 about?
NCT00269048 is a clinical study titled "SB-480848 In Subjects With Coronary Heart Disease". This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of SB-480848 on other circulating biomarkers associated with cardiovascular risk...
What is the current status of trial NCT00269048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 969 participants. The study started on 2005-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00269048?
The interventions under investigation include: placebo (DRUG), SB-480848 (DRUG).
Who is sponsoring clinical trial NCT00269048?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00269048's enrollment target sits among peer trials
969 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia